4/A//SEC Filing
LO FRANCIS 4/A
Accession 0001780660-26-000002
CIK 0001478320other
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 8:52 PM ET
Size
17.8 KB
Accession
0001780660-26-000002
Insider Transaction Report
Form 4/AAmended
LO FRANCIS
Chief People Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-22$7.80/sh+1,100$8,580→ 317,078 total - Exercise/Conversion
Common Stock
2025-12-22$8.46/sh+1,100$9,306→ 318,178 total - Exercise/Conversion
Common Stock
2025-12-22$3.99/sh+2,194$8,754→ 320,372 total - Sale
Common Stock
2025-12-22$17.50/sh−4,394$76,895→ 315,978 total - Exercise/Conversion
Stock Option (right to buy)
2025-12-22−1,100→ 112,150 totalExercise: $7.80Exp: 2029-05-06→ Common Stock (1,100 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-12-22−1,100→ 108,076 totalExercise: $8.46Exp: 2033-03-06→ Common Stock (1,100 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-12-22−2,194→ 107,981 totalExercise: $3.99Exp: 2034-03-04→ Common Stock (2,194 underlying)
Holdings
- 2,500(indirect: By Spouse)
Common Stock
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- [F2]The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $17.49 to $17.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The option is fully vested and exercisable.
- [F4]The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- [F5]The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Documents
Issuer
Adaptive Biotechnologies Corp
CIK 0001478320
Entity typeother
Related Parties
1- filerCIK 0001780660
Filing Metadata
- Form type
- 4/A
- Filed
- Jan 6, 7:00 PM ET
- Accepted
- Jan 7, 8:52 PM ET
- Size
- 17.8 KB